PMC7154263_01
Complete response of the right supraglottic and pharyngeal lesion, with previous compromise on the vallecula, aryepiglottic fold, and right side of the epiglottis after treatment with intensity-modulated radiotherapy plus cetuximab.
cro-0013-0314-g01.jpg
PMC7154263_01_cro-0013-0314-g01.jpg
F1
A complete response after 4 months of initiation was observed (Fig. 1).
Oral lesions, leukocyte counts and subpopulations at the start of symptoms (A), after administration of etoposide (B), and after systemic treatment with metronomic cyclophosphamide and oral rinse with colchicine (C). D Microbiome diversity study at the same time points.
cro-0013-0314-g02.jpg
PMC7154263_01_cro-0013-0314-g02.jpg
F2
The lesions rapidly progressed, the inferior lip (with recurrent bleeding) and almost 50% of the mucosal membrane were compromised (Fig. 2A-C). Transitory pain improvement without any changes in the ulcer distribution was noted (Fig. 2B). The patient's blood lymphocyte count was measured and divided into CD8+ and CD3+ populations at different time points (at the start of symptoms, t1; after the administration of etoposide, t2; after systemic treatment with metronomic cyclophosphamide and oral rinse with colchicine, t3) (Fig. 2A-C). Shortly after the beginning of treatment, an almost complete remission of the lesions and optimal pain control was achieved (Fig. 2C).
A Oral ulcer contained and surrounded by polymorphonuclear cells and confined cell debris; outside this zone and extending diffusely throughout the lamina propria, a large number of infiltrating lymphocytes and macrophage-like cells were seen (x40). B Inflammatory cell infiltrate (CD8+ stained; antibody CONFIRM anti-CD8, SP57) associated with oral mucosa ulceration (x10).
cro-0013-0314-g03.jpg
PMC7154263_01_cro-0013-0314-g03.jpg
F3